The Valley Desk

ArticleLeukemiaPublished

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Leukemia
Published
PubMed ID
42827117
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal